In the present study, competitive cDNA library screening (CCLS) and cDNA microarray analyses were employed to identify dierentially expressed genes in methylnitrosourea-induced rat mammary adenocarcinomas. The preliminary screening of 100 000 plaques by CCLS identi®ed 1217 clones with dierential expression. Dot ± blot analysis of the isolated clones veri®ed dierential expression in 471 distinct genes. Con®rma-tion of these 471 genes was conducted by performing reverse transcription-polymerase chain reactions, and a total of 160 genes were con®rmed after comparing six rat mammary adenocarcinomas and three normal rat mammary glands. Fifty-nine of these showed lower expression in the adenocarcinomas while the remaining 101 were overexpressed in the tumors. Employing a cDNA microarray containing 588 known genes revealed an additional 33 dierentially expressed genes in these tumors. Importantly, most of the identi®ed genes demonstrated relatively reproducible overexpression or underexpression in individual tumors. Many of the altered genes determined by cDNA microarray analysis were oncogenes, tumor suppressor genes, or genes involved in cell cycle control and apoptosis. CCLS identi®ed many others not previously associated with mammary carcinogenesis, including a novel gene named . Preliminary studies to determine the applicability of this gene expression approach for detecting potential biomarkers for cancer chemoprevention was evaluated in rat mammary tumors obtained from animals treated with vorozole, a potent aromatase inhibitor. When genes exhibiting dierential expression as determined by CCLS or cDNA microarray analysis were examined in control and vorozole-treated tumors, expression of 19 genes was found to be modulated signi®cantly in tumors treated with vorozole. Further investigations into these identi®ed genes should con-
Introduction
Although the molecular pathways of breast cancer development are still unclear, many reproducible genetic alterations have been detected in human breast cancers (Schultz and Weber, 1999) . Such alterations include ampli®cation of oncogenes, inactivation of tumor suppressor genes, and alterations in breast cancer susceptibility genes. Furthermore, nonrandom allelic loss at 1p & 1q, 3p, 11p, 13q, 17p, 17q, 18q has been observed in human breast cancer, indicating the possible involvement of potential tumor suppressor genes located in those chromosomal regions (Schultz and Weber, 1999; Van de Vijver and Nusse, 1991; Easton et al., 1993; Yamashita et al., 1993) . Often genes which have been shown to be ampli®ed are associated with concomitant increased expression of those speci®c genes. In addition, there are a wide variety of genes whose expression is altered when comparing human breast cancers with normal mammary gland or isolated breast epithelia (Sager et al., 1994; Sager, 1997; Hu et al., 1997; Nacht et al., 1999; Martin et al., 2000; Bertucci et al., 2000) . Most of these genes are probably altered at the transcription level, and may play important roles in breast cancer development. For example, maspin is a protease inhibitor which prevents proteins secreted by cancer cells from digesting the cell wall (Sager et al., 1996; Maass et al., 2000) . Maspin, which is normally expressed only in normal breast epithelial cells, is an eective tumor marker to distinguish in situ ductal cancers from invasive cancers (Maass et al., 2000) .
While many genes with altered expression may play a role during the early stages of the carcinogenic process and may play major causative roles in the development of breast cancer, abnormal expression of many genes later in the tumorigenic process may be a down-stream manifestation of regulation by other genetically altered genes. In either case, identi®cation of dierentially expressed genes in mammary adenocarcinomas may: (1) shed light on mechanisms of breast cancer development and progression; (2) facilitate the development of potential targets for prevention and therapy; and (3) identify genes whose altered expression during treatment may be indicative of ecacy of therapeutic and preventative agents used.
The rat model of methylnitrosourea (MNU)-induced mammary adenocarcinomas is a well-established animal model for breast cancer, with multiple hormonally responsive mammary tumors developing in each MNU-treated animal (Gould, 1995; Russo and Russo, 1996) . These tumors exhibit similarities with the human ER+ breast tumors including: (1) similar histopathology; (2) site of origin; and (3) response to various hormonal manipulations, e.g., ovariectomy, tamoxifen, pregnancy, and so forth (Gould, 1995; Russo, 1996, 2000; Schedin et al., 2000; Thompson et al., 2000) . Consequently, this animal model has been used extensively for evaluating preventative and therapeutic agents of breast cancer Dukes, 1997) . For example, the ecacy of vorozole, a speci®c nonsteroidal competitive aromatase inhibitor, in prevention and treatment of breast cancer was evaluated using this rodent model (De Coster et al., 1992; Lubet et al., 1994 Lubet et al., , 1998 Christov et al., 2000) . De Coster et al. (1992) demonstrated complete regression of mammary tumors following 42 days of vorozole treatment which was recently con®rmed by other groups (Lubet et al., 1998; Christov et al., 2000) . In further studies, vorozole proved to be profoundly eective in inhibiting the development of MNU-induced rat mammary adenocarcinomas (495% at a dose of 2.5 mg/kg body weight per day) . Lower doses of vorozole resulted in a dose-dependent inhibition of tumor formation, and decreased cancer multiplicity by *50% at doses as low as 0.08 mg/kg body weight per day (Lubet et al., 1998) . Vorozole is approximately 1000-fold more potent than aminoglutethimide, the ®rst generation aromatase inhibitor, against rodent and human mammary tumors (Wouters et al., 1990) . It speci®cally inhibits estrogen production without eects on other steroid biosynthetic enzymes (Cole and Robinson, 1990) . Although it is clear that reduction of estrogen synthesis accounts for the eects of vorozole, there is little known about its ability to modulate gene expression.
The objectives of the present study were: (1) to detect and identify dierentially expressed genes in rat mammary adenocarcinomas; and (2) to determine whether expression of these genes was modulated by the preventative and therapeutic agent, vorozole.
Results
Two MNU-induced rat mammary adenocarcinomas were used to screen dierentially expressed genes against two surrounding normal mammary glands using the CCLS assay (Figure 1a ,b) and the Atlas rat cDNA expression array (Figure 2 ). For CCLS assay, about 100 000 clones were examined with two sets of labeled cDNA probes. One set was a mixture from a a-32 PdCTP labeled cDNA derived from an MNU-induced mammary tumor and unlabeled RNA derived from a normal mammary gland. The other set was prepared from a mixture of a a-32 P-dCTP labeled cDNA from a normal mammary gland and a non-labeled cDNA prepared from an equal amount of total RNA from normal mammary tissue. After the CCLS screening, 1217 clones were found to have at least a twofold dierence in expression in adenocarcinomas as compared to normal tissues ( Figure 1b ). Of these clones, 471 genes were con®rmed by dot ± blot hybridization analysis ( Figure 1c) . All of the clones were subjected to sequence analysis, which frequently identi®ed several clones to be part of the same gene. RT ± PCR veri®ed semi-quantitatively 160 independent genes with dierential expression in mammary adenocarcinomas. For each gene, six MNU-induced rat mammary tumor samples and three normal samples were examined by RT ± PCR. Sixty-six of these clones were identi®ed as known genes by sequence alignment BLAST analysis against the Genbank database and they are listed in Table 1 . The identi®ed clones were considered as known genes if the clone had at least a 90% homology with known rat sequences, 70% homology with known mouse sequences or 50% homology with known sequences of other species. Figure 3a shows four dierentially expressed genes, three of which have a lowered expression in mammary tumors, while one is over-expressed. CCLS also identi®ed 94 rat unknown sequences whose dierential expression in mammary tumors were con®rmed semi-quantitatively by RT ± PCR. These studies show reproducible changes for many identi®ed genes such as phosphodiesterase I, selenoprotein, ferritin, and ets-1 as shown in Figure 3a . An important aspect of these studies is that individual tumors exhibited a fairly reproducible overexpression or underexpression of the dierentially expressed genes. As shown in Tables 1 and 2 , most of the changes in gene expression are statistically signi®cant (P50.05, P50.01 or P50.001). We have also included genes that contain obvious changes using RT ± PCR but not statistically signi®cant due to either low incidence or high variation of the observed changes. Further veri®cation of dierential gene expression in mammary tumors by Northern blot analysis could not be performed due to the limited amount of tumor tissues available for the present study.
One of the`unknown' genes was named the Rat Mammary Tumor-7 (RMT-7) gene. As shown in Figure 4a , we obtained full-length cDNA sequence of the RMT-7 gene using DNA sequencing analysis of the cDNA clone that contained the gene. Figure 4a ). Complete HMT-7 and MMT-7 sequences were obtained through the sequencing analysis of PCR products of human and mouse mammary tissue cDNAs using PCR primers speci®c for RMT-7. The RMT-7 did not exhibit homology with known functional domains when searching the Protein ± BLAST database (NCBI, NIH). The RMT-7 gene was underexpressed in rat mammary adenocarcinomas (Figure 4b ). Furthermore, this gene was also under expressed in mouse hepatomas and skin squamous cell carcinomas (unpublished data). The RMT-7 gene was expressed at a relatively high level in normal liver, kidney and heart as compared to other tissues ( Figure  4c ). This result suggests that underexpression of the RMT-7 gene is associated with carcinogenesis of mammary glands. Dierential hybridization was performed against the Atlas rat cDNA expression array, which contains 588 genes with known functions on each membrane ( Figure  2 ). Dierential expression of 77 genes was observed that showed at least a twofold alteration in expression between normal and tumor samples. Thirty-three genes were con®rmed by RT ± PCR (Table 2) . Twenty-four genes showed over-expression in rat mammary adenocarcinomas, while the remaining nine genes showed under-expression patterns in the tumors. Figure 3b illustrates the RT ± PCR results of four clones identi®ed by use of the Atlas cDNA expression array.
There is a possibility that some of the dierentially expressed genes are due to dierences in the density of rat mammary epithelial cells in normal mammary glands and in mammary tumors relative to stromal and adipose cells. Accordingly, we conducted RT ± PCR analysis of ®ve genes [angiotensin converting enzyme (ACE), fatty acid binding protein (FABP), cyclin D1, erbB2/neu, and stromelysin 3] using isolated epithelial cells derived from normal rat mammary and mammary tumors to test whether similar changes in gene expression occur. Figure 3c shows the results of RT ± PCR analysis of ACE, FABP and cyclin D1 genes using rat mammary tumor epithelial cell isolates from three tumors and normal mammary epithelial cell isolates from two normal mammary glands. Dierential expression was found for all six genes analysed using the cell isolates. This result indicates that lower percentage of rat mammary epithelial cells in normal mammary glands vs those from mammary tumors did not aect the expression data obtained in the study.
Next, we examined possible modulation of gene expression by vorozole treatment in MNU-induced mammary tumors by comparing the expression of genes in tumors derived from MNU control rats to tumors from rats treated with MNU and vorozole. The comparison involved examining dierential gene expression in control and vorozole treated tumors Figure 1 Analysis of dierentially expressed genes in rat mammary adenocarcinomas using CCLS. (a) Schematic illustration of CCLS. Equal amounts of total RNAs from rat mammary tumors and normal tissues were converted to cDNA probes with incorporation of P 32 into the cDNA strands during reverse transcription. Two competitors were also generated from normal rat mammary gland using the same procedure except for P 32 incorporation. Probes 1 and 2 were used to perform dierential hybridization against a rat ovary cDNA library. (b) An example of data from CCLS. Two identical ®lters were dierentially hybridized with the cDNA probes. The left one represents the hybridization with the probe generated from normal tissue, while the right one represents the hybridization with the probe derived from a mammary tumor. The two spots pointed with arrows show two dierentially expressed clones that were identi®ed by CCLS. (c) Results of dot ± blot Analysis. Dot ± blot analysis was conducted as one con®rmation step. The three arrows show examples of dierential expression of three identi®ed and con®rmed clones. The dots in the square frame are GAPDH which was used as a control employing those genes which we had identi®ed as being dierentially expressed in tumor and normal mammary tissue either by CCLS or by cDNA microarray analysis (Table 3) . Initially, two control tumors from the MNU-only-treatment group and two tumors from the highest vorozole dosage treatment group (0.31 mg/kg body weight/day) were used for screening. RT ± PCR reactions were subsequently applied on the selected clones for a larger set of tumors treated with MNU and vorozole as a veri®cation step (Figure 5a, b) . As shown in Table 3 , nineteen clones were con®rmed as exhibiting dierential expression as determined by RT ± PCR. One interesting ®nding is that roughly 60% of these genes show modulated expression in more than two-thirds of the tumors examined. Both increases and decreases in gene expression were observed when comparing tumors from MNU plus vorozole treated rats in contrast to rats treated with MNU alone. Figure 5a ,b shows four genes whose expression was altered by vorozole. Two of the genes showing altered expression did not bear signi®cant homology to known sequences and are, therefore, Figure 2 Analysis of dierentially expressed genes in rat mammary adenocarcinomas using cDNA microarray analysis. Dierential hybridization was performed on pairs of identical rat cDNA array membranes. (a) Shows hybridization data with the tumor probe and (b) shows the hybridization result with the probe generated from normal rat mammary tissue (Figure 5b ). These results indicate that vorozole can modulate genes that have altered expression in MNUinduced mammary tumors, and such modulation may be correlated with its chemopreventive eect.
Discussion
In this study, we screened 100 000 phage plaques against a rat ovary cDNA library by using the CCLS technique (Hu et al., 1997) . The initial screening employed two individual rat mammary tumors compared with two individual normal mammary glands. One shortcoming of this approach was the use of a cDNA library from rat ovary rather than from rat mammary (which was not available commercially). Therefore, certain genes whose expressions were altered in the mammary tumors may not be identi®ed if they are not expressed in the rat ovary. Nevertheless, a total of 1217 clones were detected with at least twofold dierence in expression in mammary tumors during the preliminary screening. Dot ± Blot analyses resulted in 471 con®rmed clones. This re¯ects in part that one may identify multiple independent clones that code for the same gene. RT ± PCR veri®ed 164 individual genes with dierential expression. The con®rmation rate of the study is about 34%. Simultaneously, dierential hybridization to a rat cDNA expression array of 588 known genes was also conducted. This revealed 41 known genes with dierential expression in rat mammary adenocarcinomas vs normal mammary glands. Combining the advantage of CCLS to identify novel sequences and cDNA array to examine genes with known function makes this study potentially valuable.
The CCLS is relatively non-selective in that radioactively labeled tumor cDNA and non-labeled normal mammary gland cDNA are hybridized against a cDNA library (Hu et al., 1997 ). The cDNA library competed against in the present study was from rat ovary and contained approximately 1.5 million phage clones. This procedure allows one to readily identify clones corresponding to novel genes. Certain limitations associated with this approach includes: (1) Since the cDNA library was not normalized, one may repeatedly pick up multiple copies of the same gene. In fact, of 1217 clones identi®ed, only 471 distinct clones were found after sequencing analyses. Thus, approximately 60% of the clones represented more than one copy of the same gene; (2) The hybridization is against an ovarian cDNA library and thus RNAs which are dierentially expressed in breast tissue may not be represented in the ovarian cDNA library; (3) Approximately 100 000 of 1 million plaques were examined. Thus, only 10% of the library were screened and RNA species that were expressed at low frequency may not be identi®ed. About 1200 plaques were identi®ed as dierentially expressed, and 43% of the genes arè unknown' (showing limited homology with known sequences in rat, mouse or man). Thus, the CCLS method can readily identify`unknown' genes showing dierential and higher levels of expression, but is less likely to identify`relevant' genes (e.g. oncogenes, cell cycle genes, transcription factors) that are expressed at low levels.
The second approach which we employed was a limited`directed' cDNA microarray from Clontech. This array, which includes a variety of oncogenes, cell cycle genes and apoptotic genes, has been utilized for detection of dierentially expressed genes in human gliomas and cell biology studies .2) and mouse (partially from NCBI: gi/12833138/dbj/AK0022851.1/AK002851); (b) Expression of the RMT-7 gene in rat mammary adenocarcinomas. Lanes 1 and 2, normal mammary glands; 3 ± 6, rat mammary adenocarcinomas; (c) Expression of the RMT-7 gene in multiple rat tissues. Northern blot analysis revealed that RMT-7 had ubiquitous expression in all rat organs examined with relatively high expression in the liver. Lanes 1, heart; 2, brain; 3, spleen; 4, lung; 5, liver; 6, skeleton muscle; 7, kidney; and 8, testis Incidence is the number of tumors had changes out of number of tumors tested. . Out of 588 genes examined 41 displayed dierential expression. The limited and selective nature of this cDNA array does not allow for identi®cation of unknown genes or patterns of genes which can be identi®ed with`non-selective' procedures. Nevertheless the procedure, with con®rmation by RT ± PCR, allows one to readily identify`relevant' genes at limited cost.
Although we identi®ed more than 205 genes showing altered expression, we will discuss a more limited set. As shown in Tables 1 and 2 , there were 99 known genes identi®ed by CCLS and cDNA microarray studies. Many of them have known functions, some of which are correlated with tumorigenesis in the mammary gland or in other organ site. An important question with regard to any potential marker is its reproducibility. As shown in the various ®gures, the expression changes for many of the genes are highly reproducible in multiple individual tumors. These ®ndings support the idea that certain of these genes may prove useful as biomarkers for therapeutic and preventative interventions. The speci®c genes discussed below are only examples of dierentially expressed genes.
One group of genes are the oncogenes and tumor suppressor genes. The Ets-1 gene was overexpressed in all six rat mammary tumors examined. Ets-1 is a transcription factor downstream of Ras in the MAPK signaling pathway (Wasylyk et al., 1998) , and plays a critical role in cell growth and development. Prior studies showed that the expression of Ets-1 was associated with the invasive potential of breast cancer cell lines (Gilles et al., 1997) . Our ®nding that Ets-1 was overexpressed in mammary cancers provides further con®rmation of Ets-1 in mammary carcinogenesis. The erbB2/neu gene was overexpressed. ErbB2/ neu overexpression has been reported in more than 50% of ductal carcinoma in situ lesions (Ramachandra et al., 1990) and 30% of invasive breast cancers. Some studies have correlated the over-expression of erbB2/ neu with a poor prognosis in breast cancer (Slamon et al., 1989) . The ®nding of over-expression of erbB2/neu in our study demonstrates certain parallels in gene expression between MNU-induced rat mammary tumors and human breast carcinomas.
Another groups of genes with dierential expression are related to cell cycle control. The key components to control the cell cycle machinery are cyclins and cyclindependent kinases (CDKs). Cyclin D1 was overexpressed in six of six tumors examined (Figure 3a,c) . The overexpression of cyclin D1 at the RNA level con®rms prior studies showing that the protein is overexpressed in rat mammary tumors as determined by Western blot analysis. Expression of Cyclin D1 is induced by mitogens and appears to be part of the Ras ± Raf ± Map kinase signal transduction cascade (Matsushime et al., 1991; Liu et al., 1995; Filmus et al., 1994) . Increased D-type cyclins then complex with CDK4 or CDK6 and activate these kinases, which initiate pRB phosphorylation and facilitate G1/S transition in the cell cycle. Cyclin D1 is also overexpressed in human breast cancer (Devilee et al., 1994) and transgenic mice overexpressing cyclin D1 develop hyperplasia and dysplasia in the mammary glands (Wang et al., 1994) .
While there are positive cell cycle regulators to promote cell cycle advancement, negative cell cycle regulators are equally important in cell cycle control (Ekholm and Reed, 2000) . The various cdk inhibitors are important genes in this category. p27/kip1 associates with cyclin D-Cdk4, cyclin E-Cdk2 assembly and abrogates their activity and was increased in four of six rat mammary tumors (Ekholm and Reed, 2000) . The up-regulation of p27 found in our study cannot be explained at present. p15 INK4B , which is involved in TGF-b-induced cell cycle arrest (Hannon and Beach, 1994) , was down-regulated in rat mammary tumors, suggesting loss of cell cycle control in the tumor cells.
One immediate application of this gene expression pro®le is to determine the possible modulation of tumor-speci®c expression pro®les by therapeutic or preventative agents. We previously demonstrated both chemopreventive and chemotherapeutic activity of vorozole on MNU-induced rat models of mammary carcinogenesis (Lubet et al., 1998; Christov et al., 2000) . In this study, we report that tumors, which grew out in the presence of low doses of vorozole, an aromatase inhibitor that blocks estrogen production, exhibit changes in 19 genes which displayed altered expression (Tables 1 ± 3 ). If we had screened MNU control tumors as compared to tumors from vorozole treated rats by CCLS or microarray, we might have identi®ed additional genes with modulated expression. This study was conducted to determine whether we could identify genes whose expression was modulated by vorozole among those genes we initially identi®ed by CCLS and microarray. Nine of the 19 were unknown genes showing less than 50% homology with known sequences in the GenBank. As shown in Figure  3 , the sulfated glucoprotein I (SGP-1) gene was overexpressed in MNU-induced rat mammary adenocarcinomas and down-regulated by vorozole in a dosedependent fashion. Selenoprotein P was upregulated by vorozole. Induction of selenoprotein P may provide more protection from oxidant damage and decrease the risk of mammary tumor formation (Burk et al., 1997; Koga et al., 1998) . Insulin-like growth factor binding protein I (IGFBP1) was decreased in tumors treated with the highest dose of vorozole. IGFBP-1 was found to be upregulated by estrogen (Suikkari et al., 1991; Martikainen et al., 1992) , the down-regulation of IGFBP-1 seen in our study could be due to a reduced estrogen production by vorozole. This result is in agreement with the ®nding that tamoxifen downregulates the expression of IGFBP-1. Presumably if we had looked for dierential expression of estrogen related genes, e.g. PS2, we might have observed additional estrogen-speci®c gene expression changes.
In summary, this study presents a pro®le of dierentially expressed genes in MNU-induced rat mammary adenocarcinomas. We identi®ed a gene designated RMT-7, which bears extensive amino acids sequence homology to a human hypothetical protein and a mouse cDNA. This gene is expressed at signi®cantly lower levels not only in rat mammary adenocaricnomas but also in mouse hepatomas and skin squamous cell carcinomas (unpublished data). Some of the identi®ed genes have functions that might explain their altered expression in mammary adenocarcinomas, while many others are, for the ®rst time, reported to be associated with mammary carcinogenesis. We also found that expression of these genes is modulated in tumors treated with vorozole. This is of importance since one of the primary objectives of the study was to determine if we could identify genes that could be modulated by chemopreventive agents. These results clearly demonstrate that screening of a limited number of tumors can identify various genes that may be useful as molecular targets for chemoprevention as well as potential biomarkers for ecacy.
Materials and methods

Rat mammary tumors
At 50 days of age, female Sprague-Dawley rats received a single i.v. injection of MNU in acidi®ed saline (pH, 5.0) at a dose of 50 mg/kg body weight. At necropsy (150 days after MNU), a portion of each rat mammary tumor (approximately 100 ± 200 mg) was collected and frozen at 7808C. The remaining tumor tissues were processed for pathological examinations. In the vorozole study, various doses of vorozole (0.08, 0.16, 0.31 and 0.63 mg/kg body weight) were administered daily (by gavage) starting at 43 days of age and continuing throughout the duration of the study . The rats in this study also received MNU at 50 days of age. At termination of this experiment (160 days after MNU), a portion of each mammary tumor (100 ± 200 mg) was also frozen and stored at 7808C. All mammary tumors used from these studies were diagnosed as adenocarcinomas.
Isolation of rat mammary cells
The procedures for isolating normal mammary epithelial cells and mammary tumor cells have been reported (Grubbs and Moon, 1974) . Brie¯y, the abdominal-inguinal mammary glands (approximately 1 gram) were rapidly excised and placed on a glass slide resting on ice. Lymph nodes were removed and the mammary tissue minced with scissors. Tissue specimens were placed in an incubation solution containing Medium 199, 2.8% sodium bicarbonate and collagenase Type II (35 mg/g tissue). The¯ask was incubated in a Dubno metabolic shaking incubator for 1 ± 1.5 h at 378C with shaking at 160 oscillations per min. The incubation solution with the digested tissue was centrifuged at 4006g for 20 min. The cell pellet was resuspended in 0.9% sodium chloride and centrifuged (procedure repeated twice). After the ®nal wash, cells were transferred to a polypropylene centrifuge tube for RNA extraction. For the tumors, the quantity of collagenase was increased to 70 mg/g tissue and the time of incubation in collagenase was increased to 1 ± 2 h.
RNA isolation
Normal mammary tissues and adenocarcinomas were collected and subjected to total RNA isolation. Total RNA was isolated as described (Hu et al., 1997) . The quantity and purity of the RNA was measured by spectrophotometer at wavelengths of 260 and 280 nm. The quality of the RNA was monitored on a formaldehyde agarose gel. DNase (Promega (Madison, WI, USA) treatment was carried out under the following conditions: mixture of total RNA in 100 ml RNase free water, 20 ml of 106DNase buer, 10 ml DNase (1 unit/ ml) and 70 ml deionized water were incubated at 378C for 30 min, followed by extraction with phenol/chloroform. RNA was then precipitated at 7208C for 1 h using 0.1 volume of 3 M sodium acetate (pH 5.0) and 2.5 volumes of 100% ethanol.
Labeling of cDNA by reverse transcription (RT)
For hybridization set 1, 5 mg DNase treated total RNA from tumors was converted to cDNA with incorporation of [a-32 P]dCTP. Labeled tumor RNA was mixed with an equal amount of RNA from normal mammary gland that had been converted to cDNA without incorporation of [a- 32 P]dCTP. For hybridization set 2, 5 mg total RNA from normal mammary gland was converted to cDNA with incorporation of [a- 32 P]dCTP. Labeled normal RNA was mixed with equal amount of RNAs from normal mammary gland that has been converted to cDNA without incorporation of [a- 32 P]dCTP. Labeling was done following a typical ®rst-strand cDNA synthesis protocol: 5 mg of total RNA was mixed with 2 ml 500 ng/ml oligo-dT primers in 10 ml of 26reverse transcription buer (40 mM Tris . Cl, pH 8.4, 10 mM KCl, 5 mM MgCl 2 , 10 mM DTT, 0.2 mg/ml BSA, 0.5 mM of dCTP, dATP, dGTP, 0.05 mM of dTTP, and 0.45 mM of either 10 mCi [a-32 P]dCTP or cold dCTP) containing 200 U of MMLV reverse transcriptase (Gibco BRL, Gaithersburg, MD, USA). The reactions were incubated at 378C for 1 h. The labeling mixture was puri®ed through a G-50 column.
Competitive hybridization against rat ovary cDNA library
A rat ovary cDNA library (Stratagene) was used as the hybridization target. The library contains approximately 1.5 million colonies, and a total of 200 plates with 500 clones on each plate were screened. The library was plated out on LB medium, and then transferred to nitrocellulose ®lters (two replicas were made for each plate). The ®lters were denatured in 1.5 M NaCl/0.5 N NaOH, and neutralized in 2.5 M NaCl/ 1 M Tris (pH 7.4). Hybridization: The ®rst replica membrane was hybridized in a solution containing the labeling mixture for hybridization set 1 and hybridization buer (56SSC, 1 Denhardt's solution, 100 mg herring sperm DNA and 50% formamide). The second replica was hybridized with the labeling mixture for hybridization set 2 and hybridization buer. The hybridization was allowed to proceed at 428C overnight with rotation. Washing stringency was 16SSC/1% SDS three times for 20 min at room temperature, followed by 0.16SSC/0.1% SDS twice for 30 min. at 558C. The ®lters were exposed to X-ray ®lms for 3 days.
Dot ± blot analysis
Clones dierentially expressed in mammary tumors vs normal mammary tissues were selected for further con®rmation. Small scale isolation of the clone was performed by following the protocol provided by Stratagene Co. Approximately 2 mg DNA was denatured by adding 0.1 volume of 2 M NaOH, 2 mM EDTA and neutralized by adding 0.1 volume of 3 M sodium acetate (pH 5.0). The denatured DNA from these clones was spotted to the nitrocellulose membrane with HYBRI.DOT Manifold Apparatus (Life Technologies Co.). Two identical membranes were made. These membranes were hybridized with probes prepared as described above for dierential screening of cDNA library.
DNA sequencing
The candidate clones for dierentially expressed genes were sequenced directly using a Sequenase version 2.0 DNA sequencing kit purchased from USB (Cleveland, OH, USA). Speci®c sequencing primers were synthesized according to the sequence of cloning vector arms. DNA sequences from these clones were compared with the sequences in NIH/GenBank using the Blast-program.
Differential hybridization of Atlas rat cDNA expression arrays
Five mg DNase treated total RNA from each sample was used and mixed with 1 ml CDS primer (0.02 mM) from Clontech (Palo Alto, CA, USA). RNA and primer mix was incubated in a 708C water bath for 3 min and transferred to a 488C heating block for another 3 min. Then, 6 ml of 56Reaction Buer (Gibco BRL, Gaithersburg, MD, USA), 3 ml of 106dNTP (Clontech), 100 mM DTT (Gibco BRL), 8 ml a-32 P-dATP and 3 ml of MMLV reverse transcriptase (Gibco BRL) were added and incubated at 378C for 1 h. The reaction was stopped by adding 3 ml 106Termination Mix (Clontech). To purify the labeled cDNA, each reaction was subjected to column chromatography using Chroma Spin-200 Depc-H 2 O (Atlas cDNA Expression Arrays User Manual, Clontech). Array membranes were pre-hybridized in a solution of ExpressHyb and sheared herring sperm DNA (Clontech) at 688C for 30 min. Equal amounts of cDNA (1610 6 c.p.m./ml) from each sample were then hybridized to identical Atlas Rat cDNA. Expression array membranes in separate hybridization tubes for 18 h at 688C. Array membranes were washed 36 in wash solution 1 (2xSSC and 1% SDS) for 30 min at 688C, followed by one wash in Solution 2 (0.16SSC and 0.5% SDS) at 688C for 30 min. The array membranes were then exposed to a Phosphor Image screen for 48 h. The signals collected by the screen were analysed by computer software ImageQuant Version 1.11.
RT ± PCR
Two mg of total RNA was used to synthesize cDNA in a total volume of 30 ml. After incubation of the RNA in 19 ml of DEPC-treated water at 658C for 10 min, the following components were added: 45 nM oligo-dT 1 ml, 56 reaction buer (50 mM Tris . Cl, pH 8.3, 75 mM KCl), 0.6 ml 50 U/ml RNase inhibitor and 2 ml 200 U/ml M-MLV reverse transcriptase. The reaction mixture was incubated at 378C for 1 h. The reaction was then terminated at 958C for 10 min. We performed comparative multiplex PCR to semi-quantitatively evaluate the gene expression dierences. In comparative multiplex PCR, primer pairs from the control cDNA, GAPDH, and the target gene cDNA would be included in each reaction at equivalent concentrations. The coampli®ca-tion of the control cDNA and the target gene cDNA in tumor and normal tissues would provide a means to control for PCR ampli®cation and enabled the relative level of the target gene expression to be quanti®ed. A pair of primers speci®c for rat GAPDH cDNA was used as an internal control. Prior to PCR, one primer from each pair (GAPDH and target gene) was 5'-end labeled with T4 polynucleotide kinase (United States Biochemical, Cleveland, OH, USA). Forty pmol of each target primer pair and GAPDH primer pair was then combined with 1 ml aliquot of cDNA, 100 mM of each deoxyribonucleotide (dATP, dCTP dGTP, and dTTP), 1.0 unit of Taq DNA polymerase (Promega, Madison, WI, USA), 50 mM KCl, 10 mM Tris-HCl (pH 9.0), and 0.1% Triton X-100. A reaction volume of 20 ml is subjected to 18 ± 24 cycles of PCR-ampli®cation. Each cycle consisted of 1 min at 948C, 2 min at 578 ± 608C and 1 min at 728C. To determine the linear range of each PCR reactions, a series of 3 ± 4 PCR reactions using 18, 20, 22, or 24 cycles were performed each target gene, and one of the reactions ®ts into the linear range was used for further quantitation. Approximately 2.5 ml reaction mixture from each PCR was loaded on the 8% polyacrylamide gel and run at 60 W for about 2 h. Gels were dried and exposed to a Phosphor Image screen for 48 h. The signals collected by the screen were analysed by computer software ImageQuant Version 1.11. The relative intensities of the target products were then normalized to the level of GAPDH control. The normalized intensities of normal mammary glands and those of tumors were compared to assess for gene expression dierences (fold). For hard copy of the image, dried gels were also exposed to X-ray ®lms.
Statistical analysis
After normalization to the level of GAPDH cDNA ampli®cation in the multiplex PCR reactions using cDNAs from both normal mammary glands and rat mammary tumors, Student's t-test was used to determine the dierence in the signal intensity of phosphor imaging between normal mammary glands and rat mammary tumors.
